

Interview Summary	Application No.		Applicant(s)	
	09/865,420		OHKUBO ET AL.	
	Examiner		Art Unit	
	Binta M. Robinson		1625	

All participants (applicant, applicant's representative, PTO personnel):

- (1) Binta M. Robinson. *BMR* (3) Thomas Cunningham. *TC*
 (2) Vince Shire. *VKS* (4) Alan Rotman.

Date of Interview: 12/20/02

Type: a) ☐ Telephonic b) ☐ Video Conference
 c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.
 If Yes, brief description: _____.

Claim(s) discussed: 1-21.

Identification of prior art discussed: _____.

Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) ☐ It is not necessary for applicant to provide a separate record of the substance of the interview(if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Alan L. Rotman
ALAN L. ROTMAN
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

 Examiner's signature, if required

(AKS)
will consider addressing

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: It was agreed that the 112, 2nd paragraph issues would be corrected. Applicant's representative agreed to address the 112, 1st paragraph issues by narrowing the scope of the phrase "5 or 6 -membered N-containing heterocyclic group containing 1 to 3 nitrogen atoms" in claim 1 and all other claims and the phrase "heteromonocyclic group containing 1 to 4 nitrogen atom(s) which may have one or more suitable substituent(s), unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom (s) which may have one or more suitable substituents" to the rings exemplified in the specification. Applicant's representative agreed to limit the phrase "immune diseases" to specific diseases exemplified in the specification and the term "metastasis" to specific tumours exemplified in the specification and supported with cell lines. The applicant's representative also agreed to eliminate the term "prevention" in claim 17. Applicant's representative also agreed to put the "Use" claims in the proper US format.

(VKS)
will consider eliminating

(VKS)
will consider limiting